To test if EZH2 inhibition enhanced the effect of olaparib in primary BRCA-deficient tumor cells, we treated Lin−CD34+ cells from patients with BRCA-deficient AML and from healthy donors with olaparib with or without UNC1999. Here, EZH2 is linked to acute myeloid leukemia.